Trial reportPloS one2026
Ketogenic effects of milk protein-coated medium-chain triglycerides in healthy men: A randomized, double-blind, crossover study.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medium-chain triglycerides (MCTs) have ketogenic effects and are reportedly effective in improving cognitive and physical functions. We hypothesized that coating the MCT microparticles with protein can enhance their absorption in the intestinal tract and their ketogenic effects. This randomized, double-blind, crossover study examined the ketogenic effects of a single intake of milk protein-coated MCT (coated MCT) in healthy adults. Participants ingested 6 g of coated MCT or untreated MCT. Then, we measured the blood levels of ketone bodies and medium-chain fatty acids and gastrointestinal symptoms up to 6 h later. The coating treatment did not significantly affect the area under the curve of change in blood total ketone bodies (TKB) (primary outcome) (P > 0.05). Meanwhile, the maximum concentration of changes in TKB, β-hydroxybutyrate, acetoacetate, and octanoic acid (secondary outcome) was significantly higher in coated MCT than in untreated MCT (P < 0.05). Furthermore, TKB positively correlated with octanoic acid (P < 0.05). Both coated and untreated MCT showed mild gastrointestinal symptoms, with no significant difference observed between the groups (P > 0.05). Coated MCT may enhance the ketogenic effect and can be safely consumed. These findings are expected to support the development of new ketogenic therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.